CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed
Drug / intervention
blood transfusionprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00000592
NCT00000592Phase 3Completed
CompareCT.gov

Stroke Prevention in Sickle Cell Anemia (STOP 1)

Augusta University·interventional·Posted Oct 28, 1999·Updated Dec 23, 2015

In Brief

A Phase 3 clinical trial evaluating blood transfusion for Anemia, Sickle Cell and 4 related conditions. Completed.

Detailed Summary

To reduce episodes of first time stroke by 75 percent in children with sickle cell anemia by the administration of prophylactic transfusion therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnemia, Sickle Cell, Cerebral Embolism and Thrombosis, Cerebrovascular Disorders, Hematologic Diseases, Hemoglobinopathies
Countries--
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI)

Timeline

Phase 3CompletedFinished
1994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 28, 1999
Enrollment StartJul 1, 1994
Study CompletionAug 1, 2000
TodayJul 2, 2026
Posted 26.7 years ago

Interventions

blood transfusionprocedure